132 related articles for article (PubMed ID: 15175797)
1. Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Zarychanski R; Houston DS
Thromb Haemost; 2004 Jun; 91(6):1115-22. PubMed ID: 15175797
[TBL] [Abstract][Full Text] [Related]
2. Intraindividual consistency of the activated protein C resistance phenotype.
Tosetto A; Simioni M; Madeo D; Rodeghiero F
Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
[TBL] [Abstract][Full Text] [Related]
3. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Ivey LM; Thom JY; Ivey JG; Baker RI
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
[TBL] [Abstract][Full Text] [Related]
4. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors.
Taralunga C; Gueguen R; Visvikis S; Regnault V; Sass C; Siest G; Lecompte T; Wahl D
Br J Haematol; 2004 Aug; 126(3):392-7. PubMed ID: 15257712
[TBL] [Abstract][Full Text] [Related]
6. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of phenotype resistance to activated protein C (APC resistance)].
Hudecek J; Ivanková J; Dobrotová M; Hybenová J; Pullmann R; Kubisz P
Vnitr Lek; 1999 Dec; 45(12):723-8. PubMed ID: 10951849
[TBL] [Abstract][Full Text] [Related]
8. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.
Mahmood A; Needham J; Prosser J; Mainwaring J; Trebble T; Mahy G; Ramage J
Eur J Gastroenterol Hepatol; 2005 Jul; 17(7):739-44. PubMed ID: 15947551
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
Strandberg K; Svensson PJ; Ohlin AK
Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
[TBL] [Abstract][Full Text] [Related]
11. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
Rolla R; Vidali M; Meola S; Pollarolo P; Pergolini P; Bellomo G
Clin Lab; 2011; 57(9-10):711-7. PubMed ID: 22029186
[TBL] [Abstract][Full Text] [Related]
12. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
13. The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
Tosetto A; Castaman G; Cappellari A; Rodeghiero F
Thromb Haemost; 2000 Nov; 84(5):811-4. PubMed ID: 11127861
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Guasch JF; Lensen RP; Bertina RM
Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
[TBL] [Abstract][Full Text] [Related]
15. Reduced factor V concentration and altered FV1/FV2 ratio do not fully explain R2-associated APC-resistance.
Govers-Riemslag JW; Castoldi E; Nicolaes GA; Tans G; Rosing J
Thromb Haemost; 2002 Sep; 88(3):444-9. PubMed ID: 12353074
[TBL] [Abstract][Full Text] [Related]
16. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
[TBL] [Abstract][Full Text] [Related]
17. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
18. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
Bergrem A; Dahm AE; Jacobsen AF; Mowinckel MC; Sandvik L; Sandset PM
Br J Haematol; 2011 Jul; 154(2):241-7. PubMed ID: 21564075
[TBL] [Abstract][Full Text] [Related]
19. Acquired activated protein C resistance caused by lupus anticoagulants.
Saenz AJ; Johnson NV; Van Cott EM
Am J Clin Pathol; 2011 Sep; 136(3):344-9. PubMed ID: 21846908
[TBL] [Abstract][Full Text] [Related]
20. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
